Statistiche di base
| CIK | 1419554 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bone Biologics Corporation - Equity Warrant
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commi |
|
| September 4, 2025 |
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook Exhibit 99.1 Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook BURLINGTON, Mass. (September 4, 2025) – Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stoc |
|
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration Statement No. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40899 Bone Biologics Co |
|
| June 30, 2025 |
Form of Series D Warrant dated June 30, 2025 Exhibit 4.1 FORM OF SERIES D COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: June 30, 2025 THIS SERIES D COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| June 30, 2025 |
Bone Biologics Announces Closing of $5.0 Million Public Offering Exhibit 99.2 Bone Biologics Announces Closing of $5.0 Million Public Offering BURLINGTON, Mass., June 30, 2025 — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or commo |
|
| June 30, 2025 |
Form of Pre-Funded Warrant dated June 30, 2025 Exhibit 4.3 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: June 30, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d |
|
| June 30, 2025 |
Form of Series E Warrant dated June 30, 2025 Exhibit 4.2 FORM OF SERIES E COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: June 30, 2025 THIS SERIES E COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| June 30, 2025 |
Form of Securities Purchase Agreement dated June 27, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 27, 2025, between Bone Biologics Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| June 30, 2025 |
Filed pursuant to Rule 424(b)(4) File No. 333-288282 PROSPECTUS BONE BIOLOGICS CORPORATION 793,750 Shares of Common Stock 456,250 Prefunded Warrants to purchase 456,250 Shares of Common Stock 456,250 Shares of Common Stock underlying the Prefunded Warrants 1,250,000 Series D Warrants to purchase 1,250,000 Shares of Common Stock 1,250,000 Shares of Common Stock underlying the Series D Warrants 1,25 |
|
| June 30, 2025 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commissio |
|
| June 30, 2025 |
Form of Placement Agent Warrant dated June 30, 2025 Exhibit 4.4 FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: June 30, 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a |
|
| June 30, 2025 |
Bone Biologics Announces Pricing of $5.0 Million Public Offering Exhibit 99.1 Bone Biologics Announces Pricing of $5.0 Million Public Offering BURLINGTON, Mass., June 27, 2025 – Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents i |
|
| June 26, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commissio |
|
| June 26, 2025 |
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements Exhibit 99.1 Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements BURLINGTON, Mass. (June 26, 2025) — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has re |
|
| June 24, 2025 |
Exhibit 4.16 FORM OF SERIES D COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: , 2025 THIS SERIES D COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [the Stockholde |
|
| June 24, 2025 |
Form of Placement Agent Warrant Exhibit 4.19 FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [ |
|
| June 24, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Bone Biologics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Fees Previously Paid Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Equity Common Stock, $0. |
|
| June 24, 2025 |
Exhibit 4.18 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date se |
|
| June 24, 2025 |
Exhibit 4.17 FORM OF SERIES E COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: , 2025 THIS SERIES E COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [the Stockholde |
|
| June 24, 2025 |
As filed with the Securities and Exchange Commission on June 24, 2025 As filed with the Securities and Exchange Commission on June 24, 2025 Registration Statement No. |
|
| June 24, 2025 |
Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 June 24, 2025 VIA EDGAR U. |
|
| June 24, 2025 |
Form of Securities Purchase Agreement Exhibit 10.19 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2025, between Bone Biologics Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| June 24, 2025 |
As filed with the Securities and Exchange Commission on June 24, 2025 As filed with the Securities and Exchange Commission on June 24, 2025 Registration Statement No. |
|
| June 24, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Fees Previously Paid Security Type Security Class Title(1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par value $0. |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BONE BIOLOGICS CORPORATION Bone Biologics Corporation, a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Law (the “DGCL”), does hereby certify as follows: FIRST: The name of the corporation is Bone Biologics Corporation (the “Corporation”). S |
|
| June 6, 2025 |
Bone Biologics Announces 1-for-6 Reverse Stock Split Exhibit 99.1 Bone Biologics Announces 1-for-6 Reverse Stock Split BURLINGTON, Mass., June 6, 2025 — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-6. The reverse stock split will take effect as of 12:0 |
|
| May 30, 2025 |
Second Amendment to the Bone Biologics Corporation 2015 Equity Incentive Plan Exhibit 10.1 SECOND AMENDMENT TO THE BONE BIOLOGICS CORPORATION 2015 EQUITY INCENTIVE PLAN The Bone Biologics 2015 Equity Incentive Plan (the “Plan”) is hereby amended as follows, effective May 30, 2025: 3. Section 3(a)(i) of the Plan is hereby amended and restated in its entirety to provide as follows: “(i) Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of sh |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commission |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40899 Bone Biologics C |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 11, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2025 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commissio |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 1, 2025 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commissi |
|
| March 17, 2025 |
As confidentially submitted to the Securities and Exchange Commission on March 17, 2025. |
|
| March 17, 2025 |
March 17, 2025 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington D.C. 20549 Re: Bone Biologics Corporation — Draft Registration Statement on Form S-1 Ladies and Gentlemen: On behalf of Bone Biologics Corporation (the “Company”), we hereby confidentially submit a draft Registration Statement on Form S-1 (the “Registration Statement”), relating to the proposed offering of sh |
|
| February 26, 2025 |
Exhibit 21.1 List of Subsidiaries The following is a list of all of the subsidiaries of Bone Biologics Corp., a Delaware corporation: ● Bone Biologics, Inc. incorporated in the state of California |
|
| February 26, 2025 |
Bone Biologics Corporation Insider Trading Policy Exhibit 19.1 BONE BIOLOGICS CORPORATION INSIDER TRADING POLICY INTRODUCTION Bone Biologics Corporation and its subsidiaries (the “Company”) is subject to various federal and state laws and regulations governing trading in its securities. It is the policy of the Company to comply fully, and to assist its employees in complying fully, with these laws and regulations. This Policy applies to all membe |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40899 Bone Biologics Corporation |
|
| December 13, 2024 |
BONE BIOLOGICS CORPORATION Up to $832,009 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-265872 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated September 27, 2024, to Prospectus dated July 11, 2022) BONE BIOLOGICS CORPORATION Up to $832,009 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated July 11, 2022, filed as a part of our registration statement on Form S-3 (File No. 3 |
|
| December 13, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commi |
|
| November 14, 2024 |
BBLG / Bone Biologics Corporation / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Bone Biologics Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 098070501 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the approp |
|
| November 14, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share of Bone Biologics Corporation shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to su |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40899 Bone Biologi |
|
| November 13, 2024 |
SC 13G/A 1 ea022071802-13ga1intrabone.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bone Biologics Corporation (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 098070501 (CUSIP Number) September 30, 2024 (Date of Event Which |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commis |
|
| October 21, 2024 |
Exhibit 99.1 Bone Biologics Appoints Phillip T. Meikle to its Board of Directors Brings 30+ years of commercial experience in the orthopedic and spine industry BURLINGTON, Mass. (October 21, 2024) — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to t |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commiss |
|
| September 27, 2024 |
BONE BIOLOGICS CORPORATION Up to $1,143,121 of Shares Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to prospectus dated July 11, 2022) Registration No. |
|
| September 27, 2024 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT September 27, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Bone Biologics Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agreement and any T |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Comm |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Comm |
|
| August 22, 2024 |
Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 August 22, 2024 VIA EDGAR U. |
|
| August 12, 2024 |
As filed with the Securities and Exchange Commission on August 12, 2024 As filed with the Securities and Exchange Commission on August 12, 2024 Registration Statement No. |
|
| August 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Bone Biologics Corporation (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40899 Bone Biologics Co |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| August 2, 2024 |
Form of Placement Agent Warrant dated August 2, 2024 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 2, 2024 |
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds Exhibit 99.1 Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds BURLINGTON, Mass. (August 2, 2024) — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commissi |
|
| August 2, 2024 |
Form of Inducement Letter Agreement dated August 1, 2024. Exhibit 10.1 Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 August 1, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Bone Biologics Corporation (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive new warrants to purchase shares |
|
| August 2, 2024 |
Form of New Warrant dated August 2, 2024 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 28, 2024 |
BBLG / Bone Biologics Corporation / Ionic Ventures, LLC - SC 13G/A Passive Investment SC 13G/A 1 g084313sc13g.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Bone Biologics Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 098070501 (CUSIP Number) June 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropri |
|
| June 20, 2024 |
Exhibit 99.1 First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion Reminder: Management “CEO Chat” with Zacks Small-Cap Research Analyst Begins Today at 11 a.m. Eastern Time BURLINGTON, Mass. (June 20, 2024) — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine |
|
| June 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commissio |
|
| May 14, 2024 |
Amendment No. 1 to Employment Agreement dated December 17, 2021 between the Company and Deina Walsh Exhibit 10.3 AMENDMENT to LETTER AGREEMENT THIS AMENDMENT No. 1 (this “Amendment”), to the Letter Agreement dated December 17, 2021 (the “Agreement”), by and between Bone Biologics Corporation, a Delaware Corporation (the “Company”), and Deina H. Walsh (the “Executive”) is effective as of March 11, 2024. Capitalized terms used but not defined herein shall have the meanings assigned to such terms i |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40899 Bone Biologics C |
|
| May 14, 2024 |
Exhibit 10.2 March 11, 2024 Personal and Confidential Jeffrey Frelick Dear Mr. Frelick: We are pleased to present you with this amended and restated letter agreement (the “Amended Letter Agreement”) setting forth the terms under which Bone Biologics Corporation (the “Company”) is agreeing to continue to employ you in the position of Chief Executive Officer (“CEO”). As you know, you originally ente |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commissi |
|
| March 14, 2024 |
EX-99.1 2 ea020185401ex99-1bone.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agre |
|
| March 14, 2024 |
BBLG / Bone Biologics Corporation / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment SC 13G 1 ea0201854-13gintrabone.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bone Biologics Corporation (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 098070501 (CUSIP Number) March 4, 2024 (Date of Event Which Requires Filing of this Statem |
|
| March 6, 2024 |
Bone Biologics Announces Pricing of $2.0 Million Public Offering Exhibit 99.1 Bone Biologics Announces Pricing of $2.0 Million Public Offering BURLINGTON, Mass., March 4, 2024—Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in li |
|
| March 6, 2024 |
Form of Placement Agent Warrant dated March 6, 2024 Exhibit 4.3 FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: March 6, 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a |
|
| March 6, 2024 |
Form of Warrant dated March 6, 2024 Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: [] Issue Date: March 6, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth ab |
|
| March 6, 2024 |
Bone Biologics Announces Closing of $2.0 Million Public Offering Exhibit 99.2 Bone Biologics Announces Closing of $2.0 Million Public Offering BURLINGTON, Mass., (March 6, 2024)—Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock (or common |
|
| March 6, 2024 |
Form of Securities Purchase Agreement dated March 4, 2024 Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 4, 2024, between Bone Biologics Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and |
|
| March 6, 2024 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commissio |
|
| March 6, 2024 |
Form of Pre-Funded Warrant dated March 6, 2024 Exhibit 4.2 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: [] Issue Date: March 6, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| March 4, 2024 |
Filed pursuant to Rule 424(b)(4) File No. 333-276771 PROSPECTUS BONE BIOLOGICS CORPORATION 119,000 Shares of Common Stock 662,251 Prefunded Warrants to purchase 662,251 Shares of Common Stock 662,251 Shares of Common Stock underlying the Prefunded Warrants 781,251 Common Warrants to purchase 781,251 Shares of Common Stock 781,251 Shares of Common Stock underlying the Common Warrants 46,875 Placeme |
|
| March 1, 2024 |
Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 March 1, 2024 VIA EDGAR U. |
|
| March 1, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commissio |
|
| March 1, 2024 |
Bone Biologics Reports Progress with NB1 Clinical Program Exhibit 99.1 Bone Biologics Reports Progress with NB1 Clinical Program BURLINGTON, Mass. (March 1, 2024) – Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion. Following Human Research Ethics Committee (HREC) approval last year in Australia |
|
| February 29, 2024 |
Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 February 29, 2024 VIA EDGAR U. |
|
| February 28, 2024 |
Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 February 28, 2024 VIA EDGAR U. |
|
| February 27, 2024 |
Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 February 27, 2024 VIA EDGAR U. |
|
| February 26, 2024 |
Engagement Agreement between H.C. Wainwright & Co., LLC and the Company dated October 30, 2023 Exhibit 10.18 Execution Version October 30, 2023 STRICTLY CONFIDENTIAL Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 Attn: Jeffrey Frelick, Chief Executive Officer Dear Mr. Frelick: This letter agreement (this “Agreement”) constitutes the agreement between Bone Biologics Corporation (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright |
|
| February 26, 2024 |
As filed with the Securities and Exchange Commission on February 26, 2024 As filed with the Securities and Exchange Commission on February 26, 2024 Registration Statement No. |
|
| February 26, 2024 |
Exhibit 10.19 Execution Version February 6, 2024 STRICTLY CONFIDENTIAL Reference is hereby made to that certain engagement letter, dated as of October 30, 2023 (the “Engagement Letter”), by and between Bone Biologics Corporation (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Engagement Let |
|
| February 23, 2024 |
Form of Placement Agent Warrant Exhibit 4.13 FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date:, 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| February 23, 2024 |
Exhibit 4.11 FORM OF COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date:, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Ini |
|
| February 23, 2024 |
Exhibit 4.12 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date:, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set |
|
| February 23, 2024 |
As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration Statement No. |
|
| February 23, 2024 |
Form of Securities Purchase Agreement Exhibit 10.17 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2024, between Bone Biologics Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| February 21, 2024 |
Policy for the Recovery of Erroneously Awarded Compensation Exhibit 97 BONE BIOLOGICS CORPORATION Policy for the Recovery of Erroneously Awarded Compensation This Policy for the Recovery of Erroneously Awarded Compensation Policy (this “Policy”) has been adopted by the Board of Directors (the “Board”) of Bone Biologics Corporation, a Delaware corporation (the “Company”), in accordance with the requirements of the Recovery Rules to implement a written policy for the recovery of erroneously awarded compensation received by executive officers in the event of an accounting restatement. |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40899 Bone Biologics Corporation |
|
| February 14, 2024 |
BBLG / Bone Biologics Corporation / Walleye Capital LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
BBLG / Bone Biologics Corporation / Ionic Ventures, LLC - SC 13G/A Passive Investment SC 13G/A 1 g084055sch13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Bone Biologics Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 098070501 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the ap |
|
| February 13, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share of Bone Biologics Corporation shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to su |
|
| February 13, 2024 |
BBLG / Bone Biologics Corporation / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bone Biologics Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 098070501 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropr |
|
| January 30, 2024 |
Form of Series B Warrant (October 2022) Exhibit 4.6 [FORM OF SERIES B COMMON STOCK PURCHASE WARRANT] BONE BIOLOGICS CORPORATION SERIES B COMMON STOCK PURCHASE WARRANT Warrant Shares: Initial Exercise Date: October 12, 2022 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condition |
|
| January 30, 2024 |
As filed with the Securities and Exchange Commission on January 30, 2024 As filed with the Securities and Exchange Commission on January 30, 2024 Registration Statement No. |
|
| January 30, 2024 |
Form of Indemnification Agreement Exhibit 10.2 FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement, dated , is made between Bone Biologics, Corporation, a Delaware corporation (the “Company”), and (the “Indemnitee”). RECITALS A. The Company desires to attract and retain the services of talented and experienced individuals, such as Indemnitee, to serve as directors and officers of the Company and its subsidiaries and w |
|
| January 30, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Bone Biologics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| January 30, 2024 |
Form of Series C Warrant (October 2022) Exhibit 4.7 [Form of SERIES C COMMON STOCK PURCHASE WARRANT] BONE BIOLOGICS CORPORATION SERIES C COMMON STOCK PURCHASE WARRANT Warrant Shares: Initial Exercise Date: October 12, 2022 THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condition |
|
| January 30, 2024 |
Form of Series A Warrant (October 2022) Exhibit 4.5 [FORM OF SERIES A COMMON STOCK PURCHASE WARRANT] BONE BIOLOGICS CORPORATION SERIES A COMMON STOCK PURCHASE WARRANT Warrant Shares: Initial Exercise Date: October 12, 2022 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condition |
|
| January 30, 2024 |
Form of Warrant (October 2021) Exhibit 4.2 [FORM OF GLOBAL CERTIFICATE] UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND A |
|
| January 22, 2024 |
Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 Bone Biologics Corporation 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 January 22, 2024 VIA EDGAR U. |
|
| January 17, 2024 |
As filed with the Securities and Exchange Commission on January 17, 2024 As filed with the Securities and Exchange Commission on January 17, 2024 Registration Statement No. |
|
| January 17, 2024 |
Securities Purchase Agreement (November 2023) Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 16, 2023, between Bone Biologics Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commis |
|
| January 11, 2024 |
Exhibit 99.1 Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors Brings 20+ years of experience in finance and business operations at both public and private life sciences companies BURLINGTON, Mass. (January 11, 2024) — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commiss |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commiss |
|
| January 10, 2024 |
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements Exhibit 99.1 Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements BURLINGTON, Mass. (January 10, 2024) — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has r |
|
| January 5, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Bone Biologics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| January 5, 2024 |
Form of Warrant (November 2023) Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 5, 2024 |
As filed with the Securities and Exchange Commission on January 5, 2024 As filed with the Securities and Exchange Commission on January 5, 2024 Registration Statement No. |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commi |
|
| December 20, 2023 |
BBLG / Bone Biologics Corporation / Ionic Ventures, LLC - SC 13G/A Passive Investment SC 13G/A 1 g083896sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Bone Biologics Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 098070501 (CUSIP Number) November 16, 2023 (Date of Event which Requires Filing of this Statement) Check the app |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commi |
|
| December 18, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BONE BIOLOGICS CORPORATION Bone Biologics Corporation, a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Law (the “DGCL”), does hereby certify as follows: FIRST: The name of the corporation is Bone Biologics Corporation (the “Corporation”). S |
|
| December 18, 2023 |
Bone Biologics Announces 1-for-8 Reverse Stock Split Exhibit 99.1 Bone Biologics Announces 1-for-8 Reverse Stock Split BURLINGTON, Mass., December 18, 2023 — Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8. The reverse stock split will take effect as of |
|
| December 13, 2023 |
Submission of Matters to a Vote of Security Holders, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commi |
|
| November 27, 2023 |
EX-99.1 2 ea189011ex99-1bone.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreeme |
|
| November 27, 2023 |
US0980704029 / BONE BIOLOGICS CORP / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bone Biologics Corporation (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 098070402 (CUSIP Number) November 16, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| November 20, 2023 |
Exhibit 4.5 DESCRIPTION OF SECURITIES The following is a brief description of (i) the common stock, par value $0.001 per share (the “common stock”) and (ii) warrants to purchase common stock (the “warrants”), of Bone Biologics Corporation (the “Company,” “we,” “our,” and “us”), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40899 Bone Bi |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant ☒ Filed by Party other than Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Def |
|
| November 20, 2023 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 16, 2023, between Bone Biologics Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commi |
|
| November 20, 2023 |
Form of Placement Agent Warrant (November 2023) Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 20, 2023 |
BONE BIOLOGICS CORPORATION 1,139,063 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-265872 Prospectus Supplement (To the Prospectus dated July 11, 2022) BONE BIOLOGICS CORPORATION 1,139,063 Shares of Common Stock We are offering 1,139,063 shares of our common stock, par value $0.001 per share, directly to certain institutional investors pursuant to this prospectus supplement and accompanying prospectus. Each share of common st |
|
| November 20, 2023 |
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules BURLINGTON, Mass., November 16, 2023—(BUSINESS WIRE)—Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,139,063 of its shares of |
|
| November 20, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40899 Bone Biologi |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant ☒ Filed by Party other than Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Def |
|
| October 24, 2023 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2023 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commis |
|
| October 24, 2023 |
Amendment No. 1 to the Amended and Restated Bylaws of Bone Biologics Corporation Exhibit 3.1 AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BYLAWS OF BONE BIOLOGICS CORPORATION On October 20, 2023 the Board of Directors of Bone Biologics Corporation, a Delaware corporation, approved by unanimous written consent to amend the Corporation’s Amended and Restated Bylaws as follows: 1. Section 2.8 of the Amended and Restated Bylaws is hereby amended and restated in its entirety to read |
|
| September 29, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Comm |
|
| September 15, 2023 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Bone Biologics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| September 15, 2023 |
As filed with the Securities and Exchange Commission on September 15, 2023 As filed with the Securities and Exchange Commission on September 15, 2023 Registration No. |
|
| September 12, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Comm |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40899 Bone Biologics Co |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commissio |
|
| June 26, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of Bone Biologics Corporation shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. June 26, 2023 LIND GLOBAL FUND II LP By: Lind Global Partners II L |
|
| June 26, 2023 |
BBLG / Bone Biologics Corp / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bone Biologics Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 098070402 (CUSIP Number) June 16, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| June 16, 2023 |
Bone Biologics Prices $5.0 Million Underwritten Public Offering Exhibit 99.1 Bone Biologics Prices $5.0 Million Underwritten Public Offering BURLINGTON, Mass. (June 14, 2023) – Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the pricing of an underwritten public offering of common stock. Bone Biologics is selling 2,538,071 shares of its common stock i |
|
| June 16, 2023 |
Exhibit 1.1 UNDERWRITING AGREEMENT between BONE BIOLOGICS CORPORATION and EF HUTTON, DIVISION OF BENCHMARK INVESTMENTS, LLC New York, New York June 14, 2023 EF HUTTON, division of Benchmark Investments, LLC as Representative of the several Underwriters named on Schedule I hereto 590 Madison Avenue, 39th Floor New York, New York 10022 Ladies and Gentlemen: The undersigned, Bone Biologics Corporatio |
|
| June 16, 2023 |
BONE BIOLOGICS CORPORATION 2,538,071 shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-271558 PROSPECTUS BONE BIOLOGICS CORPORATION 2,538,071 shares of Common Stock We are offering 2,538,071 shares of our common stock, at a public offering price of $1.97. Our common stock is listed on The Nasdaq Capital Market under the symbol “BBLG.” On June 14, 2023, the last reported sale price of our common stock on The Nasdaq Capital Market |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commissio |
|
| June 13, 2023 |
As filed with the Securities and Exchange Commission on June 13, 2023 As filed with the Securities and Exchange Commission on June 13, 2023 Registration Statement No. |
|
| June 13, 2023 |
BONE BIOLOGICS CORPORATION 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 June 13, 2023 BONE BIOLOGICS CORPORATION 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 June 13, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| June 13, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1)(2)(4) Amount of Registration Fee(2) Shares of Common Stock, par value $0. |
|
| June 13, 2023 |
June 13, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Bone Biologics Corp. Registration Statement on Form S-1 (File No. 333-271558) Ladies and Gentlemen: In connection with the above-captioned registration statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), EF Hutton, Division of Benchmark Investments, LLC, |
|
| June 13, 2023 |
Exhibit 4.3 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: [●], 2023 Initial Exercise Date: [●], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received , or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| June 13, 2023 |
Exhibit 1.1 UNDERWRITING AGREEMENT between BONE BIOLOGICS CORPORATION and EF HUTTON, DIVISION OF BENCHMARK INVESTMENTS, LLC New York, New York June [●], 2023 EF HUTTON, division of Benchmark Investments, LLC 590 Madison Avenue, 39th Floor New York, New York 10022 Ladies and Gentlemen: The undersigned, Bone Biologics Corporation, a corporation formed under the laws of the State of Delaware (the “Co |
|
| June 6, 2023 |
Exhibit 3.1 |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1)(2)(4) Amount of Registration Fee(2) Shares of Common Stock, par value $0. |
|
| June 6, 2023 |
Exhibit 4.3 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: [●], 2023 Initial Exercise Date: [●], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received , or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| June 6, 2023 |
Exhibit 1.1 UNDERWRITING AGREEMENT between BONE BIOLOGICS CORPORATION and EF HUTTON, DIVISION OF BENCHMARK INVESTMENTS, LLC New York, New York June [●], 2023 EF HUTTON, division of Benchmark Investments, LLC 590 Madison Avenue, 39th Floor New York, New York 10022 Ladies and Gentlemen: The undersigned, Bone Biologics Corporation, a corporation formed under the laws of the State of Delaware (the “Co |
|
| June 6, 2023 |
As filed with the Securities and Exchange Commission on June 6, 2023 As filed with the Securities and Exchange Commission on June 6, 2023 Registration Statement No. |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40899 Bone Biologics Corporation |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BONE BIOLOGICS CORPORATION (Name of Registrant a |
|
| May 1, 2023 |
Power of Attorney (included on the signature page for the initial filing) As filed with the Securities and Exchange Commission on May 1, 2023 Registration Statement No. |
|
| May 1, 2023 |
Exhibit 4.5 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: [●], 2022 Initial Exercise Date: [●], 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received , or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement BONE BIOLOGICS CORPORATION (Name of Registrant a |
|
| May 1, 2023 |
Exhibit 4.4 FORM OF SERIES D COMMON STOCK PURCHASE WARRANT BONE BIOLOGICS CORPORATION Warrant Shares: Issue Date: [●], 2022 Initial Exercise Date: [●], 2022 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received , or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| May 1, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1)(5) Amount of Registration Fee(2) Shares of Common Stock, par value $0. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 For the transition period from to Commission File Number: 001-40899 Bone Biologics Corporation |
|
| March 29, 2023 |
BBLG / Bone Biologics Corp / Hankey Don Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8) BONE BIOLOGICS CORPORATION (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 098070303 (CUSIP Number) Eugene Leydiker c/o Hankey Capital, LLC 4751 Wilshire Blvd., Suite 110 Los Angeles, California 90010 (310) 692-402 |
|
| February 14, 2023 |
US0980703039 / Bone Biologics Corp / Walleye Capital LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2023 |
US0980703039 / Bone Biologics Corp / Ionic Ventures, LLC - SC 13G/A Passive Investment SC 13G/A 1 g083401sc-13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bone Biologics Corp (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 098070303 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropria |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2022 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commi |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commi |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40899 Bone Biologics Corporat |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commis |
|
| October 25, 2022 |
Bone Biologics CEO Issues Letter to Stockholders Exhibit 99.1 Bone Biologics CEO Issues Letter to Stockholders BURLINGTON, Mass. (October 25, 2022) – Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick. To My Fellow Stockholders: I am delighted to update you on Bone Biologics’ de |
|
| October 13, 2022 |
Exhibt 4.3 FORM OF SERIES C WARRANT BONE BIOLOGICS CORPORATION SERIES C COMMON STOCK PURCHASE WARRANT Warrant Shares: Initial Exercise Date: October 12, 2022 THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| October 13, 2022 |
Exhibit 4.2 FORM OF SERIES B WARRANT BONE BIOLOGICS CORPORATION SERIES B COMMON STOCK PURCHASE WARRANT Warrant Shares: Initial Exercise Date: October 12, 2022 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2022 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commis |
|
| October 13, 2022 |
Exhibit 4.1 FORM OF SERIES A WARRANT BONE BIOLOGICS CORPORATION SERIES A COMMON STOCK PURCHASE WARRANT Warrant Shares: Initial Exercise Date: October 12, 2022 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| October 13, 2022 |
Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering Exhibit 99.1 DRAFT #1 OCTOBER 7, 2022 Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering BURLINGTON, Mass. (October 12, 2022) – Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced underwritten public offering of units of securities for total gross proceeds of $5,1 |
|
| October 12, 2022 |
US0980703039 / Bone Biologics Corp / Ionic Ventures, LLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bone Biologics Corp (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 098070303 (CUSIP Number) October 11, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| October 11, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2022 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-40899 42-1743430 (State or other jurisdiction of incorporation) (Commiss |
|
| October 11, 2022 |
Warrant Agent Agreement between the Company and Equiniti Trust Company dated as of October 7, 2022 Exhibit 4.1 WARRANT AGENT AGREEMENT This Warrant Agent Agreement (this ?Warrant Agreement?), dated as of October 7, 2022 (the ?Issuance Date?) between Bone Biologics Corp., a company incorporated under the laws of the State of Delaware (the ?Company?), and Equiniti Trust Company, a limited trust company organized under the laws of the State of New York (the ?Warrant Agent?). WHEREAS, pursuant to t |
|
| October 11, 2022 |
Form of Representative’s Warrant (October 2022) EX-1.1 2 ex1-1.htm Exhibit 1.1 BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT 3,777,778 Units Consisting of 3,777,778 Shares of Common Stock, And 3,777,778 Series A Warrants to Purchase 3,777,778 Shares of Common Stock And 3,777,778 Series B Warrants to Purchase 3,777,778 Shares of Common Stock And 3,777,778 Series C Warrants to Purchase 3,777,778 Shares of Common Stock October 7, 2022 WallachB |
|
| October 11, 2022 |
Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-267588 PROSPECTUS 3,777,778 Units Each Unit Consisting of One Share of Common Stock One Series A Warrant to Purchase One Share of Common Stock One Series B Warrant to Purchase One Share of Common Stock, and One Series C Warrant to Purchase One Share of Common Stock (and the shares of Common Stock underlying such Warrants) BONE BIOLOGICS CORPOR |
|
| October 11, 2022 |
Bone Biologics Prices $5,100,000 Underwritten Public Offering Exhibit 99.1 Bone Biologics Prices $5,100,000 Underwritten Public Offering BURLINGTON, Mass. (October 7, 2022) ? Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces the pricing of an underwritten public offering of 3,777,778 units of securities at an offering price of $1.35 per unit, for total gross proceeds of $5,100,000 , before de |
|
| October 7, 2022 |
As filed with the Securities and Exchange Commission on October 7, 2022 As filed with the Securities and Exchange Commission on October 7, 2022 Registration Statement No. |
|
| October 7, 2022 |
As filed with the Securities and Exchange Commission on October 7, 2022 As filed with the Securities and Exchange Commission on October 7, 2022 Registration Statement No. |
|
| October 7, 2022 |
Calculation of Registration Fee Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1)(7) Amount of Registration Fee(1) Units(3) $ 100,000. |
|
| October 7, 2022 |
Calculation of Registration Fee Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1)(7) Amount of Registration Fee(1) Units(3) $ 865,000. |
|
| October 5, 2022 |
Exhibit 4.2 WARRANT AGENT AGREEMENT This Warrant Agent Agreement (this ?Warrant Agreement?), dated as of [], 2022 (the ?Issuance Date?) between Bone Biologics Corp., a company incorporated under the laws of the State of Delaware (the ?Company?), and Equiniti Trust Company, a limited trust company organized under the laws of the State of New York (the ?Warrant Agent?). WHEREAS, pursuant to the term |
|
| October 5, 2022 |
Exhibit 1.1 BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT 1,923,077 Units Consisting of 1,923,077 Shares of Common Stock, And 1,923,077 Series A Warrants to Purchase 1,923,077 Shares of Common Stock And 1,923,077 Series B Warrants to Purchase 1,923,077 Shares of Common Stock And 1,923,077 Series C Warrants to Purchase 1,923,077 Shares of Common Stock October [ ], 2022 WallachBeth Capital LLC H |
|
| October 5, 2022 |
EX-FILING FEES 6 ex-107.htm CALCULATION OF REGISTRATION FEE Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1)(7) Amount of Registration Fee(2) Units(3) $ 5,000,000.00 $ 463.50 Shares of Common Stock, par value $0.001 per share, included in the Units(4) $ 5,750,000.00 633.35 Series A Warrants included in the U |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 4, 2022 As filed with the Securities and Exchange Commission on October 4, 2022 Registration Statement No. |
|
| October 4, 2022 |
Exhibit 1.1 BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT 1,923,077 Units Consisting of 1,923,077 Shares of Common Stock, And 1,923,077 Series A Warrants to Purchase 1,923,077 Shares of Common Stock And 1,923,077 Series B Warrants to Purchase 1,923,077 Shares of Common Stock And 1,923,077 Series C Warrants to Purchase 1,923,077 Shares of Common Stock October [ ], 2022 WallachBeth Capital LLC H |
|
| October 4, 2022 |
BONE BIOLOGICS CORPORATION 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 October 4, 2022 BONE BIOLOGICS CORPORATION 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 October 4, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| October 4, 2022 |
As filed with the Securities and Exchange Commission on October 4, 2022 As filed with the Securities and Exchange Commission on October 4, 2022 Registration Statement No. |
|
| October 4, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1)(6) Amount of Registration Fee(2) Units(3) $ 5,000,000. |
|
| October 4, 2022 |
Exhibit 4.2 WARRANT AGENT AGREEMENT This Warrant Agent Agreement (this ?Warrant Agreement?), dated as of [], 2022 (the ?Issuance Date?) between Bone Biologics Corp., a company incorporated under the laws of the State of Delaware (the ?Company?), and Equiniti Trust Company, a limited trust company organized under the laws of the State of New York (the ?Warrant Agent?). WHEREAS, pursuant to the term |
|
| October 4, 2022 |
October 4, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Mr. Tyler Howes Re: Bone Biologics Corporation Registration Statement on Form S-1 Filed October 4, 2022 File No. 333-267588 Dear Mr. Howes: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the ?Securities Act?), we, as representative |
|
| September 23, 2022 |
Exhibit 1.1 BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT [ ]Units Consisting of [ ] Shares of Common Stock, And [ ] Series A Warrants to Purchase [ ] Shares of Common Stock And [ ] Series B Warrants to Purchase [ ] Shares of Common Stock And [ ] Series C Warrants to Purchase [ ] Shares of Common Stock September [ ], 2022 WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson S |
|
| September 23, 2022 |
As filed with the Securities and Exchange Commission on September 23, 2022 Registration Statement No. |
|
| September 23, 2022 |
Exhibit 4.2 WARRANT AGENT AGREEMENT This Warrant Agent Agreement (this ?Warrant Agreement?), dated as of [], 2022 (the ?Issuance Date?) between Bone Biologics Corp., a company incorporated under the laws of the State of Delaware (the ?Company?), and Equiniti Trust Company, a limited trust company organized under the laws of the State of New York (the ?Warrant Agent?). WHEREAS, pursuant to the term |
|
| September 23, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1)(6) Amount of Registration Fee(2) Units(3) $ 5,000,000. |
|
| August 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-53078 42-1743430 (State or other jurisdiction of incorporation) (Commiss |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-53078 Bone Biologics Corporation ( |
|
| July 7, 2022 |
BONE BIOLOGICS CORPORATION 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 July 7,2022 BONE BIOLOGICS CORPORATION 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 July 7,2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| July 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| June 28, 2022 |
EX-FILING FEES 5 ex107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Bone Biologics Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share( |
|
| June 28, 2022 |
As filed with the Securities and Exchange Commission on June 28, 2022 As filed with the Securities and Exchange Commission on June 28, 2022 Registration Statement No. |
|
| June 28, 2022 |
Exhibit 4.7 BONE BIOLOGICS CORPORATION INDENTURE Dated as of , 20 Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 3 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 4 ARTICLE II THE SECURITIES 4 Section 2.1 Issuable in Series 4 Section 2.2 Establishment of |
|
| June 9, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-53078 42-1743430 (State or other jurisdiction of incorporation) (Commission |
|
| June 9, 2022 |
Exhibit 10.1 THIRD AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT UC Control Number 2019-04-0625 THIS THIRD AMENDMENT (the ? Third Amendment?), dated May 9, 2022 (the ? Third Amendment?s Effective Date?), is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (?The Regents?), a California corporation having its statewide administrative offices at 1111 Franklin Street |
|
| May 23, 2022 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-53078 42-1743430 (State or other jurisdiction of incorporation) (Commission |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-53078 Bone Biologics Corporation |
|
| March 15, 2022 |
Debt Conversion Agreement dated October 8, 2021 between the Company and Hankey Capital* Exhibit 10.28 DEBT CONVERSION AGREEMENT THIS DEBT CONVERSION AGREEMENT (this ?Agreement?) is made and entered into as of October 8, 2021 by and between Bone Biologics Corporation, a Delaware corporation (the ?Company?), and Hankey Capital, LLC (?Purchaser?). RECITALS A. Purchaser has made advances to the Company in the aggregate amount of $12,767,894 (the ?Advances?) evidenced by convertible notes |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 For the transition period from to Commission File Number: 000-53078 Bone Biologics Corporation |
|
| March 15, 2022 |
Exhibit 10.30 SUPPLY AND DEVELOPMENT SUPPORT AGREEMENT by and between BONE BIOLOGICS CORPORATION and MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC. Dated as of March 3, 2022 Supply AND Development support agreement THIS SUPPLY and DEVELOPMENT SUPPORT AGREEMENT (this ?Agreement?), dated as of the 3rd day of March, 2022 (?Effective Date?), is made and entered into by and between BONE BIOLOGICS CORPORAT |
|
| March 8, 2022 |
Exhibit 99.1 Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix Secures rhNELL-1 Carrier for Bone Regeneration Spine Fusion Product BURLINGTON, Mass. (March 7, 2022) ? Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has entered into a supply agreement with MTF Biologics for demineraliz |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-53078 42-1743430 (State or other jurisdiction of incorporation) (Commissio |
|
| March 8, 2022 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF BONE BIOLOGICS CORPORATION (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES |
|
| December 22, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-53078 42-1743430 (State or other jurisdiction of incorporation) (Commi |
|
| December 22, 2021 |
Employment Agreement dated December 17, 2021 between the Company and Deina Walsh Exhibit 10.1 |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-53078 Bone Biologics Corporat |
|
| November 2, 2021 |
BONE BIOLOGICS CORPORATION 1,004,310 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-257484 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus Dated October 12, 2021) PROSPECTUS BONE BIOLOGICS CORPORATION 1,004,310 Shares of Common Stock This Prospectus Supplement No. 1 amends and supplements the Prospectus dated October 7, 2021 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration stat |
|
| November 1, 2021 |
Exhibit 99.1 DEBT CONVERSION AGREEMENT THIS DEBT CONVERSION AGREEMENT (this ?Agreement?) is made and entered into as of October 8, 2021 by and between Bone Biologics Corporation, a Delaware corporation (the ?Company?), and Hankey Capital, LLC (?Purchaser?). RECITALS A. Purchaser has made advances to the Company in the aggregate amount of $12,767,894 (the ?Advances?) evidenced by convertible notes |
|
| November 1, 2021 |
BBLG / Bone Biologics Corp / Hankey Don Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7) BONE BIOLOGICS CORPORATION (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 098070204 (CUSIP Number) Eugene Leydiker c/o Hankey Capital, LLC 4751 Wilshire Blvd., Suite 110 Los Angeles, California 90010 (310) 692-402 |
|
| October 19, 2021 |
EXHIBIT 4.1 [FORM OF CERTIFICATED WARRANT] THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(d) OF THIS WARRANT. BONE BIOLOGICS CORPORATION Warrant To Purchase Common Stock Warrant No.: Date of Issuance: [ ], 2021 (?Issuance Date?) Bone Biologics Corporation, a Delaware corporation (the ?Compa |
|
| October 19, 2021 |
Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq Exhibit 99.1 Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq October 18, 2021 - BURLINGTON, Mass. ?Bone Biologics Corp. (NASDAQ: BBLG)(?Bone Biologics? or the ?Company?), a developer of orthobiologic products for spine fusion markets, today announced that it closed a public offering of 1,510,455 units of securities at an offering price of $5.25 per unit, for total |
|
| October 19, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2021 BONE BIOLOGICS CORPORATION. delaware 000-53078 42-1743430 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2 |
|
| October 15, 2021 |
Exhibit 99.1 Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split October 13, 2021 - BURLINGTON, Mass. ?Bone Biologics Corp. (NASDAQ: BBLG)(?Bone Biologics? or the ?Company?), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its underwritten public offering of 1,510,455 u |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 13, 2021 BONE BIOLOGICS CORPORATION. delaware 000-53078 42-1743430 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2 |
|
| October 15, 2021 |
Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-257484 and 333-260209 PROSPECTUS 1,510,455 Units, Each Consisting of One Share of Common Stock and a Warrant to Purchase One Share of Common Stock BONE BIOLOGICS CORPORATION Common Stock and Warrants We are offering 1,510,455 units (each a ?Unit?), each unit consisting of one share of common stock, par value $0.001 per share and one warrant (e |
|
| October 15, 2021 |
Exhibit 3.1 |
|
| October 15, 2021 |
Warrant Agent Agreement between the Company and Equiniti Trust Company dated as of October 13, 2021 Exhibit 4.1 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this ?Warrant Agreement?) dated as of [ ], 2021 (the ?Issuance Date?) between Bone Biologics Corporation, a Delaware corporation (the ?Company?), and Equiniti (the ?Warrant Agent?). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (?Underwriting Agreement?), dated [ ], 2021, by and among the Company and WallachBeth C |
|
| October 15, 2021 |
Form of Representative’s Warrant (October 2021) Exhibit 1.1 BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT 1,510,455 Units Consisting of 1,510,455 Shares of Common Stock And 1,510,455 Warrants to Purchase 1,510,455 Shares of Common Stock October 13, 2021 WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311 As Representative of the Several Underwriters Named on Schedule I hereto Ladies |
|
| October 15, 2021 |
Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-257484 and 333-260209 PROSPECTUS 1,510,455 Units, Each Consisting of One Share of Common Stock and a Warrant to Purchase One Share of Common Stock BONE BIOLOGICS CORPORATION Common Stock and Warrants We are offering 1,510,455 units (each a ?Unit?), each unit consisting of one share of common stock, par value $0.001 per share and one warrant (e |
|
| October 12, 2021 |
As filed with the Securities and Exchange Commission on October 12, 2021 As filed with the Securities and Exchange Commission on October 12, 2021 Registration No. |
|
| October 8, 2021 |
BONE BIOLOGICS CORPORATION. 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 October 8,2021 CORRESP 1 filename1.htm BONE BIOLOGICS CORPORATION. 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 October 8,2021 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-6010 Re: Bone Biologics Corporation. Registration Statement on Form S-1 (Reg. No. 333-257484) Ladies and Gentlemen: On behalf of Bone Biologics Corporation, the undersigned hereby requests |
|
| October 8, 2021 |
October 8, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Ms. Irene Paik Re: Bone Biologics Corporation Registration Statement on Form S-1 Filed October 6, 2021 File No. 333-257484 Dear Ms. Adams: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the ?Securities Act?), we, as representative |
|
| October 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Bone Biologics Corporation (Exact name of registrant as specified in its charter) Delaware 42-1743430 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification |
|
| October 7, 2021 |
Exhibit 10.39 |
